Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hepatitis C
Biotech
Atea's COVID antiviral fails to halt hospitalizations in phase 3
Atea Pharmaceuticals’ antiviral has failed another COVID-19 trial, but the biotech still holds out hope the candidate has a future in hepatitis C.
James Waldron
Sep 13, 2024 10:10am
FDA clears its first fingerstick hepatitis C diagnostic test
Jul 2, 2024 11:04am
FDA unlocks faster clearances for future hepatitis C diagnostics
Nov 22, 2021 11:21am
Gilead's virology lead Brainard jumps ship to AlloVir
Mar 23, 2021 7:25am
Ascletis poaches top MSD China exec as its new R&D chief
Mar 1, 2019 9:53am
Ascletis files for Hong Kong IPO
May 8, 2018 9:19am
